0
Your cart

Your cart is empty

Books > Medicine > Clinical & internal medicine > Diseases & disorders > Oncology

Buy Now

Chemosensitivity Testing in Oncology (Paperback, Softcover reprint of the original 1st ed. 2003) Loot Price: R4,326
Discovery Miles 43 260
Chemosensitivity Testing in Oncology (Paperback, Softcover reprint of the original 1st ed. 2003): Uwe Reinhold, Wolfgang Tilgen

Chemosensitivity Testing in Oncology (Paperback, Softcover reprint of the original 1st ed. 2003)

Uwe Reinhold, Wolfgang Tilgen

Series: Recent Results in Cancer Research, 161

 (sign in to rate)
Loot Price R4,326 Discovery Miles 43 260 | Repayment Terms: R405 pm x 12*

Bookmark and Share

Expected to ship within 10 - 15 working days

Over the past 50 years many in vitro and in vivo drug response assay systems have been developed to determine the potential - tivity of chemotherapy agents. The idea was to eliminate ineffective agents and unnecessary toxic treatment while selecting drugs active in vitro or in the mouse model that might increase the probability of response in the patient. None of these test models, however, achieved routine clinical application in the past. This might be at least in part - lated to large discrepancies that were described between the s- cess rate of the assay systems and the clinical benefit in cancer - tients. The heterogeneity of chemosensitivity that exists between different tumors as well as between individual tumor lesions may be one explanation for these findings. Furthermore, different assay end points such as proliferation, metabolism, and vitality were - veloped to evaluate the effects of cytostatic drugs on tumor cells, and these might be related to the differing results. However, knowledge about procedures for assay-assisted treatment selection has increased rapidly within the past few years, and several studies suggest that test-directed chemotherapy selection now may - prove response rates and survival in various types of tumors. The International Society for Chemosensitivity Testing in - cology (ISCO) was founded to promote, coordinate, and improve clinical and laboratory research in the field of predictive drug te- ing in human tumor cells.

General

Imprint: Springer-Verlag
Country of origin: Germany
Series: Recent Results in Cancer Research, 161
Release date: October 2012
First published: 2003
Editors: Uwe Reinhold • Wolfgang Tilgen
Dimensions: 235 x 155 x 14mm (L x W x T)
Format: Paperback
Pages: 245
Edition: Softcover reprint of the original 1st ed. 2003
ISBN-13: 978-3-642-62412-4
Categories: Books > Medicine > Clinical & internal medicine > Diseases & disorders > Oncology > General
Promotions
LSN: 3-642-62412-X
Barcode: 9783642624124

Is the information for this product incomplete, wrong or inappropriate? Let us know about it.

Does this product have an incorrect or missing image? Send us a new image.

Is this product missing categories? Add more categories.

Review This Product

No reviews yet - be the first to create one!

Partners